T helper cell

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy

Retrieved on: 
火曜日, 4月 16, 2024
ILC2, FDA, Idiopathic pulmonary fibrosis, Irritation, Blister, Hope, Safety, T helper cell, Animal, SAE, Research, JAK1, Immunoglobulin G, Therapy, Patient, EAACI, Clinical trial, Atopic dermatitis, Asthma, Immunity, FIC, Pharmaceutical industry

The publication in this international, peer-reviewed and well-cited journal Allergy establishes the scientific validity of SM17 on the treatment of AD, and highlights the potential of SM17 as a revolutionary product in this field.

Key Points: 
  • The publication in this international, peer-reviewed and well-cited journal Allergy establishes the scientific validity of SM17 on the treatment of AD, and highlights the potential of SM17 as a revolutionary product in this field.
  • The Allergy article and the results of the US Phase I study scientifically validated the favourable efficacies and good safety profile of SM17 for treating AD.
  • We are pleased that evidence demonstrating the advantageous therapeutic potential of SM17 for treating AD is scientifically confirmed and endorsed by being published on the renowned peer-reviewed journal Allergy.
  • The preclinical results will be confirmed in human in a proof of concept clinical trial in AD patients that was initiated in April 2024."

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
火曜日, 3月 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Retrieved on: 
月曜日, 2月 12, 2024
Atopic dermatitis, Immunodeficiency, Psoriasis, Infection, SQL, ITK, Scleroderma, Preprint, Asthma, T helper cell, Pulmonary fibrosis, T helper 17 cell, Venn, Lymphocyte, Cytokine, Rheumatoid arthritis, Immunosuppression, Dermatitis, Publication, Lymphoma, Research, Immunomodulation, Vaccine

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.

Key Points: 
  • BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.
  • These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function.
  • Atopic dermatitis (also called eczema) and asthma are thought to be mediated primarily by Th2 lymphocytes.
  • The soquelitinib preclinical data and information on the Company’s next-generation ITK inhibitor candidates was presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, in poster session #2 (poster #2008) at the Keystone Symposia.

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Retrieved on: 
金曜日, 12月 8, 2023
Woman, Safety, Therapy, Ottawa Hospital Research Institute, Intensity, Podium, Breast cancer, Fatigue, Patient, Gene expression profiling, Necrosis, The Ottawa Hospital, T helper cell, Immunotherapy, Breast, CD4, Gene expression, Biomarker, Mastectomy, MD, Nausea, Diagnosis, Cancer, University, Downregulation and upregulation, Neoplasm, News, Publication, Injection, NK, Vaccine, Medical imaging

"A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.

Key Points: 
  • "A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.
  • A functional pathway enrichment analysis was conducted and confirmed positive changes in T-cell activation, lymphocyte activation and inflammatory response.
  • Over 95% of treatment-emergent adverse events (TEAEs) were low grade 1 or 2 primarily localized pain, fatigue, and nausea.
  • We see the potential opportunity for our technology and drug products in both the metastatic and presurgical settings for many types of cancers."

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

Retrieved on: 
木曜日, 11月 23, 2023
CNS, Food, Asthma, Sanofi, Patient, Inflammation, Multimedia, Agreement, FDA, Marketing, Atopic dermatitis, Regeneron Pharmaceuticals, Partnership, Connect, Antibody, Knowledge, Autoimmunity, Good, Pharmaceutical industry, Fine chemical, Simcere Pharmaceutical, T helper cell

NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.

Key Points: 
  • NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.
  • Pursuant to the Agreement, Simcere obtains the exclusive rights in the development, manufacturing, and commercialization of Rademikibart for all indications in Greater China.
  • Connect will retain its rights outside Greater China and will complete the ongoing pivotal clinical trial for atopic dermatitis (AD) treatment and other ongoing clinical trials.
  • According to Simcere's announcement, this collaboration will further enhance its product portfolio in the autoimmune field and strengthen the synergistic effect in its commercialization efforts.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
火曜日, 11月 7, 2023
Allergy, Neoplasm, FDA, Research, Psoriasis, Kidney cancer, NSCLC, Scientific Reports, Carcinoma, Pulmonary fibrosis, Nivolumab, Asilomar International Conference on Climate Intervention Technologies, T helper cell, Preprint, Scleroderma, PTCL, Pembrolizumab, Head, 65th Infantry Regiment, BioRxiv, Cytokine, Time management, Ipilimumab, RCC, ITK, Society, ASH, Clinical trial, Science, Asthma, Cancer, Webcast, Lung cancer, Autoimmunity, Total, Conference call, Patient, Lymphoma, Communications satellite, Pharmaceutical industry, Vaccine, Cryptocurrency, T helper 17 cell, Corvus, Conference

BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • The paper highlights the potential of selective ITK inhibition for the treatment of cancers and helps to confirm preclinical and clinical results generated by Corvus.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the third quarter 2023 financial results.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
水曜日, 11月 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

Retrieved on: 
土曜日, 11月 4, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, Patient, MDSC, Uveal melanoma, Fatigue, Nivolumab, T helper cell, DCR, Pancreas, PFS, Liver, Skin, FACS, SITC, NanoString Technologies, NK, Liver disease, Annual general meeting, Blood, TLR, Tumor microenvironment, University, Society, Progression-free survival, MD Anderson Cancer Center, Neoplasm, Society for Immunotherapy of Cancer, Medical imaging, Pharmaceutical industry, Immunotherapy, Cancer

The Progression-Free Survival (PFS), Disease Control Rate (DCR), and ctDNA molecular response data in PERIO-01 patients in combination with nivolumab are encouraging for UMLM and for other indications under development.

Key Points: 
  • The Progression-Free Survival (PFS), Disease Control Rate (DCR), and ctDNA molecular response data in PERIO-01 patients in combination with nivolumab are encouraging for UMLM and for other indications under development.
  • At the optimal biologic dose of SD-101 (2 mg) in combination with nivolumab (n=7), the median PFS was 11.7 months with an 81% DCR.
  • At the data cutoff as of September 29, 2023, 56 patients were enrolled, with each having received at least one dose of SD-101.
  • Dr. Katz added, “These data reflect additional validation of our innovative immunotherapy approach for liver and pancreas tumors.

Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window

Retrieved on: 
金曜日, 11月 3, 2023
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pharmacology, Inc., T helper cell, Society for Immunotherapy of Cancer, Poster, Pharmacodynamics, SITC, Immunotherapy, IL-12, NK, Biology, Neoplasm, The Boy in the Bubble (novel), Annual general meeting, Toxicity, CRS, Society, Pharmaceutical industry, Vaccine, Cancer

Synthekine Inc ., an engineered cytokine therapeutics company, today presented new data from preclinical studies of STK-026, its biased IL-12 partial agonist program, during the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego.

Key Points: 
  • Synthekine Inc ., an engineered cytokine therapeutics company, today presented new data from preclinical studies of STK-026, its biased IL-12 partial agonist program, during the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego.
  • STK-026 is designed to retain the potent antitumor activity of IL-12 while avoiding its systemic toxicities and is currently in IND-enabling studies.
  • Notably, compared to wild-type IL-12 treatment, STK-026 monotherapy demonstrated a substantial improvement in therapeutic window which was associated with reduced NK activation and systemic cytokine induction.
  • The poster will be available on Synthekine’s website following presentation at the meeting.

American Lung Association Funds $13.6 Million in Research for a Future Free of Lung Disease

Retrieved on: 
木曜日, 10月 12, 2023
Havasupai Tribe v. the Arizona Board of Regents, Manning Innovation Awards, T helper cell, Immunotherapy, COVID-19, Omicron, Lung cancer, Tropism, Icahn School of Medicine at Mount Sinai, Asthma, University of Arizona, Natural killer T cell, Research, COPD, Boston University, Immunoglobulin E, University, Disease, Lung, Patient, Award, American Lung Association, CHI3L1, Canadian Lung Association, Immunology, Helminthiasis, Trustee, Research institute, Infection, SARS-CoV-2, RSV, TFH, Blood, Mount Sinai, Pharmaceutical industry, Vaccine, School

CHICAGO, Oct. 12, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today's science to end the burden of lung disease tomorrow. Lung research is critical because one in 10 people in the U.S. are living with a lung disease and each year, millions of people are impacted by respiratory viruses like COVID-19 and influenza.

Key Points: 
  • Organization funds 129 promising research grants on lung cancer, asthma, COVID-19 and more
    CHICAGO, Oct. 12, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today's science to end the burden of lung disease tomorrow.
  • Through the Awards and Grants Program, the Lung Association supports trailblazing research, novel ideas and innovative approaches.
  • The Lung Association's Awards and Grants Program promotes innovative research, collaboration, translation of discoveries and scientific exchange to transform today's science into tomorrow's solutions," said Harold Wimmer, President and CEO of the American Lung Association.
  • For more information about the new grant awardees and the entire American Lung Association research team, visit Lung.org/research-team .